ME2

Across TCGA pan-cancer cohorts, ME2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ME2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ME2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ME2 is over-expressed in tumor, although a few such as COAD and PDAC show the opposite, repressed pattern.

COAD, LSCC, and LUAD are the cancer types where ME2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ME2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	−0.226	<.001	9	view →
LSCC	Female	All	+0.360	<.001	8	view →
LUAD	Female	II,III,IV	+0.333	<.001	8	view →
HNSC	Male	All	+0.139	.001	7	view →
CCRCC	Female	IV	+0.218	.008	4	view →
OV	All	All	+0.478	.002	2	view →
PDAC	Male	IV	−0.680	<.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ME2–COAD

Open the COAD breakdown →